8-K: Guardant Health Amends Co-CEO Compensation Agreements, Introduces New Equity Awards

Guardant Health has amended the compensation agreements for its co-CEOs, replacing cash bonuses with significant annual and long-term equity awards.

Summary

• Guardant Health has updated the compensation agreements for its co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, effective January 1, 2024.
• The co-CEOs' annual base salary remains at $1.
• Instead of annual cash bonuses, the co-CEOs will receive annual grants of restricted stock units (RSUs) and performance-based stock units (PSUs), each with a dollar-denominated value of $800,000.
• The RSUs will vest quarterly over one year, and the PSUs will vest based on the achievement of annual performance goals.
• Additionally, each co-CEO will receive long-term awards of RSUs and PSUs, each with a dollar-denominated value of $5,000,000.
• The long-term RSUs will vest over 27 months, and the long-term PSUs will vest based on revenue CAGR, relative total shareholder return (TSR), and absolute TSR goals over a three-year period starting January 1, 2025.
• The previous PSU awards granted to the co-CEOs on May 26, 2020, have been cancelled.

Sentiment

Score: 7

Explanation: The document outlines a positive change in executive compensation, aligning pay with performance and long-term growth. The lack of cash bonuses may be seen as a negative by some, but overall the changes are likely to be viewed favorably by investors.

Positives

• The new compensation structure aligns executive pay with company performance through the use of performance-based stock units.
• The long-term equity awards incentivize the co-CEOs to focus on long-term growth and shareholder value.
• The vesting schedule of the RSUs and PSUs encourages continued service and commitment from the co-CEOs.

Negatives

• The co-CEOs will no longer receive annual cash bonuses, which may be seen as a reduction in immediate compensation.
• The performance-based vesting of PSUs introduces uncertainty in the ultimate value of the awards.

Risks

• The achievement of performance goals for the PSUs is not guaranteed and depends on the company's future performance.
• Changes in market conditions could impact the value of the equity awards.
• The long-term nature of the awards may not provide immediate motivation for short-term performance.

Future Outlook

Future salary compensation for the co-CEOs will be determined by the Compensation Committee after 2024. The long-term PSU awards will vest based on performance over a three-year period starting January 1, 2025.

Management Comments

• The Committee has been working on enhancements to the Severance Plan and intends to adopt the updates in the near future.
• The Committee expects to consult with the co-CEOs prior to final adoption of the updated Severance Plan.

Industry Context

The move to replace cash bonuses with equity awards is a common practice in the biotech industry to align executive compensation with long-term company performance and shareholder value. This is particularly relevant for growth-stage companies like Guardant Health.

Comparison to Industry Standards

• Many biotech companies use a mix of salary, cash bonuses, and equity awards for executive compensation.
• The use of performance-based stock units is a common practice to incentivize executives to achieve specific financial and operational goals.
• The vesting schedules for the RSUs and PSUs are fairly standard in the industry, with vesting periods ranging from one to three years.
• Companies like Exact Sciences and Illumina also use similar compensation structures for their executives, with a focus on long-term equity incentives.

Stakeholder Impact

• Shareholders may view the changes positively as they align executive pay with company performance.
• Employees may be interested in the changes to executive compensation and how it relates to their own compensation.
• The co-CEOs are directly impacted by the changes in their compensation structure.

Next Steps

• The Compensation Committee will determine future salary compensation for the co-CEOs after 2024.
• The Committee will approve the grant of the RSU and PSU awards.
• The Committee will finalize and adopt the updated Severance Plan.

Key Dates

Keywords

executive compensation, restricted stock units, performance-based stock units, equity awards, co-CEO, Guardant Health, TSR, revenue CAGR